IP Library › Granted Patent US 12,371,665
Granted Patent B2
US 12,371,665 · App. 18/824,588 · Granted Jul 29, 2025

Differentiation of pancreatic endocrine cells

Inventors: George Harb (Boston, MA); Chunhi Xie (Belmont, MA)
Assignee: Vertex Pharmaceuticals Incorporated
C12N5/0676A61K35/39C12N2501/11C12N2501/15C12N2501/155C12N2501/415
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,665
App. No.
18/824,588
Granted
Jul 29, 2025
Kind
B2
Abstract

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Claims (29)

1. A method of treating a subject having diabetes, comprising administering to the subject a composition comprising a plurality of in vitro differentiated cells in a plurality of cell clusters; wherein the cell clusters comprise a plurality of cells that express insulin; wherein at least 80% of the cells in the composition are ISL1-positive cells; wherein the cell clusters in the composition are between 75 and 250 microns in diameter, and wherein 30-70% of the cells in the composition are C-peptide positive ISL1-positive, VMAT1-negative cells.

2. The method of claim 1 , wherein less than 10% of the cells in the composition are NKX6.1-negative, ISL1-negative cells.

3. The method of claim 1 , wherein less than 6% of the cells in the composition are NKX6.1-negative, ISL1-negative cells.

4. The method of claim 3 , wherein at least 90% of the cells in the composition are ISL1-positive cells.

5. The method of claim 3 , wherein 80-95% of the cells in the composition are ISL1-positive cells.

6. The method of claim 5 , wherein 40-50%, about 45-55%, or about 50-55% of the cells in the composition are NKX6.1-negative, ISL1-positive cells.

7. The method of claim 5 , wherein 30-50% of the cells in the composition are C-peptide-positive, ISL1-positive, VMAT1-negative cells, wherein the cells were not subjected to a cell sorting process comprising subjecting the cells to flow cytometry based on a fluorescent protein expressed by the cells.

8. The method of claim 7 , wherein the composition is administered via intraportal transplanting.

9. The method of claim 7 , wherein 40-50%, 45-55%, or 50-55% of the cells in the composition are NKX6.1-negative, ISL1-positive cells.

10. The method of claim 9 , wherein the composition is administered via intraportal transplanting.

11. The method of claim 1 , wherein less than 4% of the cells in the composition are NKX6.1-negative, ISL1-negative cells.

12. The method of claim 1 , wherein at least 90% of the cells in the composition are ISL1-positive cells.

13. The method of claim 1 , wherein 3-6% of the cells in the composition are NKX6.1-negative, ISL1-negative cells.

14. The method of claim 1 , wherein 80-90% of the cells in the composition are ISL1-positive cells.

15. The method of claim 1 , wherein 85-95% of the cells in the composition are ISL1-positive cells.

16. The method of claim 1 , wherein at least 40% of the cells in the composition are NKX6.1-negative, ISL1-positive cells.

17. The method of claim 1 , wherein 40-50%, about 45-55%, or about 50-55% of the cells in the composition are NKX6.1-negative, ISL1-positive cells.

18. The method of claim 1 , wherein 30-50% of the cells in the composition are C-peptide-positive, ISL1-positive, VMAT1-negative cells.

19. The method of claim 18 , wherein the cells were not subjected to a cell sorting process comprising subjecting the cells to flow cytometry based on a green fluorescent protein expressed by the cells.

20. The method of claim 1 , wherein the cells were not subjected to a cell sorting process comprising subjecting the cells to flow cytometry.

21. The method of claim 20 , wherein the cells were not subjected to a cell sorting process comprising subjecting the cells to flow cytometry based on a fluorescent protein expressed by the cells.

22. The method of claim 1 , wherein the cell clusters are at most 200 microns in diameter.

23. The method of claim 1 , wherein the cell clusters are at most 150 microns in diameter.

24. The method of claim 1 , wherein the cell clusters are between 100 and 150 microns in diameter.

25. The method of claim 1 , wherein the cells in the composition have a genetic disruption in the beta-2-microglobulin gene.

26. The method of claim 1 , wherein the composition comprises NKX6.1-positive, ISL1-positive cells that express lower levels of MAFA than NKX6.1-positive, ISL1-positive cells from the pancreas of a healthy control adult subject.

27. The method of claim 1 , wherein the composition comprises NKX6.1-positive, ISL1-positive cells that express higher levels of MAFB than NKX6.1-positive, ISL1-positive cells from the pancreas of a healthy control adult subject.

28. The method of claim 1 , wherein the composition comprises NKX6.1-positive, ISL1-positive cells that express higher levels of SIX2, HOPX, IAPP and/or UCN3 than NKX6.1-positive, ISL1-positive cells from the pancreas of a healthy control adult subject.

29. The method of claim 1 , wherein the composition is administered via intraportal transplanting.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2024
From: HARB, GEORGE; XIE, CHUNHUI
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 068529/0776 →
Continuity (4)
Continuation 17988257 · Nov 16, 2022
Continuation 17390839 · Jul 30, 2021
Provisional Application 63059433 · Jul 31, 2020
Related Publication 20240425818A1 · Dec 26, 2024
References Cited (125)
US 8415153B2 · Majumdar et al. · 2013 [cited by applicant]
US 9062290B2 · Rezania · 2015 [cited by applicant]
US 9096832B2 · Xu · 2015 [cited by applicant]
US 9585917B2 · Martinson et al. · 2017 [cited by applicant]
US 9744195B2 · Xu · 2017 [cited by applicant]
US 10030229B2 · Peterson et al. · 2018 [cited by applicant]
US 10358628B2 · Rezania · 2019 [cited by applicant]
US 10370645B2 · D'Amour et al. · 2019 [cited by applicant]
US 10443042B2 · Melton et al. · 2019 [cited by applicant]
US 10494609B2 · Rezania · 2019 [cited by applicant]
US 10947511B2 · Rezania · 2021 [cited by applicant]
US 11085027B2 · Melton et al. · 2021 [cited by applicant]
US 11466256B2 · Pagliuca et al. · 2022 [cited by applicant]
US 11525120B2 · Pagliuca et al. · 2022 [cited by applicant]
US 11992506B2 · Harb et al. · 2024 [cited by applicant]
US 11999971B2 · Pagliuca et al. · 2024 [cited by applicant]
US 12006516B2 · Harb et al. · 2024 [cited by applicant]
US 12049645B2 · Harb et al. · 2024 [cited by applicant]
US 20070259421A1 · D'Amour et al. · 2007 [cited by applicant]
US 20080267926A1 · Martinson et al. · 2008 [cited by applicant]
US 20110008819A1 · Chipperfield et al. · 2011 [cited by applicant]
US 20140271566A1 · Agulnick et al. · 2014 [cited by applicant]
US 20150240212A1 · Peterson et al. · 2015 [cited by applicant]
US 20160177269A1 · College · 2016 [cited by applicant]
US 20160272944A1 · Ding et al. · 2016 [cited by applicant]
US 20170009210A1 · Ikeda et al. · 2017 [cited by applicant]
US 20170029778A1 · Peterson et al. · 2017 [cited by applicant]
US 20200332262A1 · Poh et al. · 2020 [cited by applicant]
US 20210017157A1 · Thiel et al. · 2021 [cited by applicant]
US 20210198632A1 · Pagliuca et al. · 2021 [cited by applicant]
US 20210214690A1 · Melton et al. · 2021 [cited by applicant]
US 20210238553A1 · Pagliuca et al. · 2021 [cited by applicant]
US 20210353686A1 · Ito et al. · 2021 [cited by applicant]
US 20210403876A1 · Pagliuca et al. · 2021 [cited by applicant]
US 20220090020A1 · Harb et al. · 2022 [cited by applicant]
US 20220162562A1 · Peterson et al. · 2022 [cited by applicant]
US 20220233646A1 · Carey · 2022 [cited by applicant]
US 20230075375A1 · Pagliuca et al. · 2023 [cited by applicant]
US 20230085395A1 · Pagliuca et al. · 2023 [cited by applicant]
US 20230092449A1 · Harb et al. · 2023 [cited by applicant]
US 20230146780A1 · Pagliuca et al. · 2023 [cited by applicant]
US 20240309330A1 · Majumdar et al. · 2024 [cited by applicant]
US 20250011723A1 · Harb et al. · 2025 [cited by applicant]
US 20250122478A1 · Harb et al. · 2025 [cited by applicant]
JP 2019068849 · 2019 [cited by applicant]
WO WO2009132083A2 · 2009 [cited by applicant]
WO WO2010002846A1 · 2010 [cited by applicant]
WO WO2011143299A2 · 2011 [cited by applicant]
WO WO2014124172A1 · 2014 [cited by applicant]
WO WO2017019702A1 · 2017 [cited by applicant]
WO 2017177163A1 · 2017 [cited by applicant]
WO 2017222879A1 · 2017 [cited by applicant]
WO WO2019018818A1 · 2019 [cited by applicant]
WO WO2019169351A1 · 2019 [cited by applicant]
WO WO2019183597A1 · 2019 [cited by applicant]
WO WO2019213366A1 · 2019 [cited by applicant]
WO WO2019217487A1 · 2019 [cited by applicant]
WO WO2019222487A1 · 2019 [cited by applicant]
WO WO2020033879A1 · 2020 [cited by applicant]
WO WO2020264072A1 · 2020 [cited by applicant]
WO WO2022026932A1 · 2022 [cited by applicant]
WO WO2022026932A2 · 2022 [cited by applicant]
WO WO2022026933A2 · 2022 [cited by applicant]
WO WO2022147056A1 · 2022 [cited by applicant]
WO WO2022192300A1 · 2022 [cited by applicant]
Zhang et al. Insulin-producing cells from human pancreatic islet-derived progenitor cells following transplantation in mice. Cell Biology International 2011, 35:483-490. (Year: 2011). [cited by examiner]
Lögdberg et al. Islet transplantation, stem cells, and transfusion medicine. Transfusion Medicine Reviews 2003, 17;2:95-109. (Year: 2003). [cited by examiner]
European Patent Office communication pursuant to Rule 114(2) EPC citing Third Party Observations in European Patent Application No. 21849911.9, 5 pages, (mailed Aug. 14, 2024). [cited by applicant]
Kumar et al., “Recent Developments in Beta-Cell Differentiation of Pluripotent Stem Cells Induces by Small and Large Molecules,” [cited by applicant]
Ma et al., “Chemical strategies for pancreatic beta cell differentiation, reprogramming, and regeneration,” [cited by applicant]
Rezania et al., “Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells,” [cited by applicant]
Thakur et al., “Small Molecule-Induced Pancreatic Beta-Like Cell Development: Mechanistic Approaches and Available Strategies,” [cited by applicant]
Al-Masri et al., Effect of forkhead box O1 (FOXO1) on beta cell development in the human fetal pancreas. Diabetologia. Apr. 2010;53(4):699-711. [cited by applicant]
Apelqvist et al., Notch signalling controls pancreatic cell differentiation. Nature. Aug. 26, 1999;400(6747):877-81. doi: 10.1038/23716. [cited by applicant]
Balboa et al., Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat Biotechnol. Jul. 2022;40(7):1042-1055. doi: 10.1038/s41587-022-01219-z. Epub Mar. 3, 2022. [cited by applicant]
Bouchi et al., FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures. Nat Commun. Jun. 30, 2014;5:4242. doi: 10.1038/ncomms5242. Author Manuscript, 24 pages. [cited by applicant]
Chen et al., A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat Chem Biol. Apr. 2009;5(4):258-65. doi: 10.1038/nchembio.154. Epub Mar. 15, 2009. [cited by applicant]
D'Amour et al., Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. Nov. 2006;24(11):1392-401. doi: 10.1038/nbt1259. Epub Oct. 19, 2006. [cited by applicant]
Hering et al., Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care. Jul. 2016;39(7):1230-40. doi: 10.2337/dc15-1988. Epub Apr. 18, 2016. [cited by applicant]
Kimura et al., Small molecule AT7867 proliferates PDX1-expressing pancreatic progenitor cells derived from human pluripotent stem cells. Stem Cell Res. Oct. 2017;24:61-68. [cited by applicant]
Nagashima et al., Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol. Nov. 2010;78(5):961-70. doi: 10.1124/mol.110.065714. E… [cited by applicant]
Sasaki et al., Transient FOXO1 inhibition in pancreatic endoderm promotes the generation of NGN3+ endocrine precursors from human iPSCs. Stem Cell Res. Apr. 2020;44:101754. [cited by applicant]
Segerstolpe et al., Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metab. Oct. 11, 2016;24(4):593-607. doi: 10.1016/j.cmet.2016.08.020. Epub Sep. 22, 2016. [cited by applicant]
Sharon et al., Wnt Signaling Separates the Progenitor and Endocrine Compartments during Pancreas Development. Cell Rep. May 21, 2019;27(8):2281-2291.e5. doi: 10.1016/j.celrep.2019.04.083. [cited by applicant]
Talchai et al., Legacy Effect of Foxo1 in Pancreatic Endocrine Progenitors on Adult β-Cell Mass and Function. Diabetes. Aug. 2015;64(8):2868-79. doi: 10.2337/db14-1696. Epub Mar. 17, 2015. [cited by applicant]
Yu et al., FoxO1 inhibition promotes differentiation of human embryonic stem cells into insulin producing cells. Exp Cell Res. Jan. 1, 2018;362(1):227-234. [cited by applicant]
Co-pending U.S. Appl. No. 18/055,327, inventors Felicia J. Pagliuca et al., filed on Nov. 14, 2022. [cited by applicant]
Co-pending U.S. Appl. No. 18/054,860, inventors Felicia Pagliuca et al., filed on Nov. 11, 2022. [cited by applicant]
Co-pending U.S. Appl. No. 18/051,721, inventors George Harb et al., filed on Nov. 1, 2022. [cited by applicant]
Co-pending U.S. Appl. No. 17/985,746, inventors Felicia J. Pagliuca et al., filed on Nov. 11, 2022. [cited by applicant]
Peterson Q.P. et al., “A Method for the Generation of Human Stem Cell-Derived Alpha Cells”, Nature Communications 11(2241): 1-14 (2020). [cited by applicant]
Schweicher J. et al., “Membrances to Achieve Immunoprotection of Transplanted Islets”, Front Biosci 29:49-76 (2014). [cited by applicant]
Street C.N. et al., “Islet Graft Assessment in the Edmonton Protocol”, Diabetes 53:3107-3114 (2004). [cited by applicant]
Street C.N. et al., “Stem Cell-Based Approaches to Solving the Problem of Tissue Supply for Islet Transplantation in Type 1 Diabetes”, The International Journal of Biochemistry & Cell Biology 36:667-683 (2004). [cited by applicant]
Vertex Press Release, “Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes”, (Jul. 11, 2022). [cited by applicant]
Wang D. et al., “Targeted Disruption of the B2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells”, Stem Cells Translational Medicine 4:1234-1245 (2015). [cited by applicant]
Invitation to Pay Additional Fees dated Oct. 21, 2021 received in International Application No. PCT/US2021/44080. [cited by applicant]
Xin Y. et al., “Pseudotime Ordering of Single Human Beta-Cells Reveals States of Insulin Production and Unfolded Protein Response”, Diabetes 67:1783-1794 (Sep. 2018) (including single-cell sequencing data stored in the … [cited by applicant]
Co-pending U.S. Appl. No. 18/391,867, inventors Yeh-Chuin Poh et al., filed on Dec. 21, 2023. [cited by applicant]
Co-pending U.S. Appl. No. 18/391,831, inventors Yeh-Chuin Poh et al., filed on Dec. 21, 2023. [cited by applicant]
Co-pending U.S. Appl. No. 18/391,799, inventors George Harb et al., filed on Dec. 21, 2023. [cited by applicant]
Akinci E. et al., “Reprogramming of Various Cell Types to a Beta-Like State by Pdx1, Ngn3 and MafA”, PLoS ONE 8(11):e82424 (Nov. 2013). [cited by applicant]
Banerjee M. et al., “A Simple Two-Step Protocol for the Purification of Human Pancreatic Beta Cells”, Diabetologia 52:621-625 (2009). [cited by applicant]
Ehrhart M. et al., “Chromogranin A in the Pancreatic Islet: Cellular and Subcellular Distribution”, The Journal of Histochemistry and Cytochemistry 34(12): 1673-1682 (1986). [cited by applicant]
Germanos M. et al., “Inside the Insulin Secretory Granule”, Metabolites 11:515 (2021). [cited by applicant]
Lee D.D. et al., “Cellular Therapies for Type I Diabetes”, Horm Metab Res. 40(2):147-154 (Feb. 2008). [cited by applicant]
Shultz M.D. et al., “Identification of NVP-TNKS656: The Use of Structure-Efficiency Relationships to Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor”, Journal of Medicinal Chemistry 56:6495-65… [cited by applicant]
Bottino R. et al., “Pancreas and Islet Cell Transplantation”, Best Practice & Research Clinical Gastroenterology 16 (3):457-474 (2002). [cited by applicant]
Pileggi A. et al., “Reversal of Diabetes by Pancreatic Islet Transplantation into a Subcutaneous, Neovascularized Device”, Transplantation 81(9):1318-1324 (Mar. 15, 2006). [cited by applicant]
U.S. Appl. No. 18/824,576, Harb and Xie. [cited by applicant]
U.S. Appl. No. 18/904,543, Harb and Xie. [cited by applicant]
Anlauf et al., “Expression of the Two Isoforms of the Vesicular Monoamine Transporter (VMAT1 and VMAT2) in the Endocrine Pancreas and Pancreatic Endocrine Tumors,” [cited by applicant]
Jensen et al., “Independent Development of Pancreatic Alpha and Beta Cell from Neurogenin3 Expressing Precursors: A Role for the Notice Pathway in Repression of Premature Differentiation,” [cited by applicant]
Velazco-Cruz et al., “Acquisition of Dynamic Function in Human Stem Cell-Derived B Cells,” [cited by applicant]
Millman et al., “Generation of stem cell-derived beta-cells from patients with type 1 diabetes,” [cited by applicant]
Co-Pending U.S. Appl. No. 18/742,930, filed Jun. 13, 2024 (Peterson et al.). [cited by applicant]
Lyttle et al., “Transcription factor expression in the developing human fetal endocrine pancreas,” [cited by applicant]
Galloway et al., “SSBP3 Interacts with Islet-1 and Ldb1 to impact pancreatic β-cell target genes,” [cited by applicant]
Agulnick et al., “Insulin-Producing Endocrine Cells Differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo,” [cited by applicant]
Gopurappilly and Bhonde, “Transcriptional profiling and functional network analyses of islet-like clusters (ILCs) generated from pancreatic stem cells in vitro,” [cited by applicant]
Huang et al., “The flaws and future of islet volume measurements,” [cited by applicant]
Marques et al., “C-peptide Much more than a byproduct of insulin biosynthesis,” [cited by applicant]
Ravassard, et al., “A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion”, [cited by applicant]
Veres, et al., “Charting cellular identity during human in vitro β-cell differentiation”, [cited by applicant]
U.S. Appl. No. 19/000,973, filed Dec. 24, 2024, Pagliuca et al. [cited by applicant]